The development came following the announcement that Panacea Biotec supplied the first shipment of the second component of the Russian Sputnik V vaccine manufactured by it for sale in India.
Dr Reddy Share Price Fall, Dr Reddy Share Price Target: Dr Reddy's share price plummeted more than 10 per cent after the company declared its first quarter results.
Dr Reddy's, which has tied up with Russian Direct Investment Fund for Sputnik V in India, soft-launched the vaccine in India in May 2021 after receiving Emergency Use Authorization (EUA) in April 2021.
Dr Reddys Laboratories Ltd, which soft-launched Russia's COVID-19 vaccine, Sputnik V on May 14 has expanded the pilot project to over 50 other cities and towns in the country.
2-deoxy-D-glucose (2DG) is an oral anti-viral drug for Covid-19 patients. The drug has generated a lot of curiosity after it was launched on May 17 by the Ministry of Defence.
Equity benchmark indices were range-bound on May 10 but closed in the green on the back of RBI's liquidity measures and indications of robust corporate earnings. At the closing bell, the BSE SandP Sensex was up by 296 points or 0.6 per cent at 49,502 while the Nifty 50 ticked higher by 119 points or 0.8 per cent to 14,942.
Once available, Sputnik V will be the third vaccine to be used in India against coronavirus. The other two vaccines are Covaxin and Covishield.
The Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) is going to meet on Wednesday afternoon to discuss Dr Reddy's Laboratories application seeking emergency use approval (EUA) for SputnikV, a Russian Vaccine.
As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21, 2021, Dr Reddy's said in a statement.
The ongoing trial was expected to be completed by February after which it would approach the Drug Controller General of India (DCGI) for EUA and based on its approval the vaccine could be launched in March, DRL's Chief Executive Officer of APIs and Pharmaceutical Services Deepak Sapra said.
Recently, RDIF had announced the second interim analysis of clinical trial data, which showed 91.4 per cent efficacy for the vaccine on day 28 after the first dose; and efficacy of over 95 per cent 42 days after the first dose.
Prime Minister Narendra Modi on Monday had a virtual meetings with 3 teams working on developing and manufacturing vaccine for COVID-19. These teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories.
Dr Reddy's Laboratories Ltd on Thursday announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Sputnik V vaccine in India.
Dr Reddy’s Laboratories recently received regulatory approvals to conduct human trials of a Covid-19 vaccine candidate developed by a Russian research institute.
An expert panel at the Central Drugs Standard Control Organisation (CDSCO) has asked Dr Reddy's Laboratories to submit a revised protocol for conducting both phase-2 and 3 human clinical trials in India for the Russian vaccine, Sputnik V, against COVID-19, sources said.
The Hyderabad-based Dr Reddy's Laboratories has applied to the Drugs Controller General of India for permission to conduct phase-3 human clinical trials of the Russian vaccine Sputnik V against COVID-19 in India, sources said.
Dr Reddy's Laboratories has announced the launch of Avigan (Favipiravir) tablets, used for COVID-19 treatment, in India. The drug major said that Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19.
Dr. Reddy's Laboratories Ltd on Saturday announced it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that will grant the city-based drug maker right to register, manufacture and sell Gilead's investigational drug, Remdesivir
Dr Reddy's Laboratories Ltd entered into a definitive agreement with Wockhardt Ltd to acquire select divisions of itsbranded generics business in India and a few other international territories, including Sri Lanka and Maldives for Rs 1850 crores, the drug maker said on Wednesday.